Concepedia

Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE

Jing Jiang, Shenjun Li, Xiaolei Shan, Ling Wang, Jinling Ma, Min Huang, Lihou Dong, Fang Chen

Toxicology Letters · 2019 · 45 citations · 10 references

DOI

Concepts

References

10

Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors

Leah N. Klapper, Mark Kirschbaum, Michael Seta et al. · Advances in cancer research · 1999 · 546 citations

, , +16

OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION

DeonJ. Venter, Sanjeev Kumar, NadiaL. Tuzi et al. · The Lancet · 1987 · 406 citations

, , +10

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer et al. · Toxicology and Applied Pharmacology · 2013 · 194 citations · Full text

, , +17

An FDA oncology analysis of antibody-drug conjugates

Haleh Saber, John K. Leighton · Regulatory Toxicology and Pharmacology · 2015 · 172 citations

, , +14

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

Xuejing Yao, Jing Jiang, Xin Wang et al. · Breast Cancer Research and Treatment · 2015 · 112 citations

, , +14